Substituted imidazolium compounds for treating disease
View Patent ↗The present disclosure relates to therapeutic compositions comprising substituted imidazoliums having multiple acidic groups. The compounds may be used to treat diseases or conditions such as those associated with bone, cancer, or pain. Compositions, dosage forms, methods of treating diseases or conditions, methods of preparation, and other related embodiments related to the substituted imidazoliums are also described herein.
1. A method of treating a disease or condition comprising administering a pharmaceutical dosage form comprising:
or a salt thereof, in an amount that is at least 1% w/w of a total amount of a therapeutically active agent in the pharmaceutical dosage form;
to a mammal in need thereof;
wherein the disease or condition comprises acute pain, central pain, radio-therapy or chemo-therapy associated neuropathy, ankylosing spondylitis, arthritis, axial spondyloarthritis, blood cancers, bone fracture, bone metastases from solid tumors, bone metastasis, breast cancer, cancer, central multiple sclerosis pain, Charcot's foot, chronic pain, complex regional pain syndrome, diabetic peripheral neuropathy, erosive osteoarthritis, excessive bone resorption, fibrous dysplasia, giant cell tumor of bone, HIV-associated neuropathy, hypercalcemia of malignancy, inflammatory pain, juvenile rheumatoid arthritis, leukemias, low back pain, lumbar nerve root compression, lumbosacral pain, lung cancer, metastatic bone cancer, monoradiculopathies, multiple myeloma, musculoskeletal pain, neuropathic arthropaties, neuropathic pain, non-articular rheumatism, osteoarthritis, osteogenesis imperfecta, osteoporosis, Paget's disease, Paget's disease of bone, peri-articular disorders, phantom limb pain, post-herpetic neuralgia, postoperative pain, post-stroke pain, prostate cancer, rheumatoid arthritis, SAPHO syndrome, sero-negative (non-rheumatoid) arthropathies, solid tumors or cancers, spinal cord injury, systemic lupus erythematosus, transient osteoarthritis of the hip, transient osteoporosis, transient osteoporosis of the hip, trigeminal neuralgia, tumor induced hypocalcemia, or vertebral crush fracture.
2. The method of claim 1 , wherein zoledronic acid is less than 95% w/w of the total amount of the therapeutically active agent present in the pharmaceutical dosage form.
3. The method of claim 1 , wherein Compound 1, or a salt thereof, is the sole therapeutically active agent present in the pharmaceutical dosage form.
4. The method of claim 1 , wherein the mammal is a human being.
5. The method of claim 1 , wherein the disease or condition comprises osteoporosis.
6. The method of claim 1 , wherein the disease or condition comprises inflammatory pain.
7. The method of claim 1 , wherein the disease or condition comprises arthritis.
8. The method of claim 1 , wherein the disease or condition comprises multiple myeloma.
9. The method of claim 1 , wherein the disease or condition comprises Paget's disease.
10. The method of claim 1 , wherein the pharmaceutical dosage form is administered orally.